ASH Clinical News April 2016 | Page 4

Calendar American Association of Cancer Research Annual Meeting April 16 – 20, 2016 New Orleans, LA The AACR Annual Meeting will highlight the latest discoveries in every area of cancer research, from molecular biology to clinical studies, epidemiology, prevention, and survivorship. International Society of Hematology’s 36th World Congress April 18 – 21, 2016 Glasgow, Scotland, UK The 36th World Congress, hosted by the British Society of Hematology, gathers international members of the hematology community to network and discuss the changing clinical and laboratory practice landscape, as well as report on advances in the field. Oncology Nursing Society Annual Congress April 28, 2016 – May 1, 2016 San Antonio, TX This year’s Annual Congress will feature the latest developments in oncology nursing and patient care, as well as networking opportunities for the more than 3,000 attendees. Highlights of ASH® Get a synopsis of the top hematology research presented at the 2015 ASH Annual Meeting and learn how it can help improve your patient management and care strategies. This is an opportunity to evaluate your diagnostic techniques and therapeutic approaches and discuss with leading hematology experts and colleagues how new research and clinical updates can be translated into patient care strategies. There is one remaining meeting this year: April 29 – 30, 2016 Porto Alegre, Brazil *Please note the change in location from what was previously published in past issues. Live: 15” ® (brentuximab ® (brentuximab ADCETRIS ADCETRIS vedotin) vedotin) forfor injection, injection, forfor intravenous intravenous use use Brief Brief Summary: Summary: seesee package package insert insert forfor complete complete prescribing prescribing information information WARNING: WARNING: PROGRESSIVE PROGRESSIVE MULTIFOCAL MULTIFOCAL LEUKOENCEPHALOPATHY LEUKOENCEPHALOPATHY (PML) (PML) JCJC virus virus infection infection resulting resulting in in PML PML and and death death can can occur occur in in patients patients receiving receiving ADCETRIS. ADCETRIS. INDICATIONS INDICATIONS AND AND USAGE USAGE Classical Classical Hodgkin Hodgkin Lymphoma Lymphoma (HL) (HL) Post-auto-HSCT Post-auto-HSCT Consolidation Consolidation ® (brentuximab ® (brentuximab vedotin) vedotin) forfor injection injection is is a CD30-directed a CD30-directed antibody-drug antibody-drug conjugate conjugate indicated indicated forfor ADCETRIS ADCETRIS thethe treatment treatment of of classical classical HLHL at at high high risk risk of of relapse